Comment: supratherapeutic response to ezetimibe administered with cyclosporine

1. Koshman SL Lalonde LD Burton I Tymchak WJ Pearson GJ. Supratherapeutic response to ezetimibe administered with cyclosporine. Ann Pharmacother 2005;39:1561–5. Epub 19 Jul 2005. DOI 10.1345/aph.1G015.

2. Bays H Drehobl M Rosenblatt S Toth P Dujovne C Knopp R Low-density lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of intestinal cholesterol absorption in 243 hypercholesteremic subjects: results of a dose–response study (abstract). Atherosclerosis 2000;151:133.

3. Data on file. Merck/Schering-Plough Pharmaceuticals, North Wales, PA.

4. Dujovne CA Bays H Davidson MH Knopp R Hunninghake DB Stein EA Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. J Clin Pharmacol 2001;41:70–8.

5. Thompson G O'Neill F Seed M. Why some patients respond poorly to statins and how this might be remedied. Eur Heart J 2002;23:200–6.

6. Product monograph and prescribing information. Lipitor (atorvastatin). New York: Pfizer. www.lipitor.com/pi/default.asp (accessed 2005 Sept 8).

7. Ziajka PE Reis M Kreul S King H. Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe. Am J Cardiol 2004;93:779–80.

8. Cheung RJ Ito MK Henry RR. Is the cholesterol lowering response to a statin and a cholesterol absorption inhibitor inversely related? A prospective, randomized, cross-over design study. Presented at: 2005 Annual Meeting of the American College of Clinical Pharmacy, Oct 26, 2005, San Francisco, CA.